Where I see patients (4)
My reviews
Selected research
-
PROX1 is an early driver of lineage plasticity in prostate cancer.
The Journal of clinical investigation
-
Pre- or post-chemotherapy: effect on PSMA uptake.
EJNMMI research
-
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025.
Journal of the National Comprehensive Cancer Network : JNCCN
Clinical trials
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
rPFS is defined as the amount of time from the initiation of study therapy and the day of first documented radiographic disease progression per RECIST version 1.1 and PCWG3 criteria. The proportion of patients without radiographic...
Recruiting
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate ...
Incidence and severity of adverse events or serious adverse events of ARX517 alone or in combination with ARPIs will be assessed to determine the safety and tolerability of the treatment using National Cancer Institute (NCI) Commo...
Recruiting
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastati...
To compare the PFS between treatment arms. PFS is defined as the time (month) interval between date of randomization and date of radiographic disease progression or death for those without prior evidence of progression, as assesse...
Recruiting
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant ...
Defined as either objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (complete response (CR), partial response (PR)) or confirmed >= 50% decline from serum prostate-specific antigen (PSA) at ...
Recruiting
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With So...
On overall response will be reported as a percentage of participants with a complete response (CR) or partial response (PR) as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Recruiting
4.9